{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:10:09Z","timestamp":1792131009036,"version":"4.4.0"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"S. Rana, Roche Diagnostics and Siemens"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Preeclampsia is a leading cause of maternal and neonatal mortality and morbidity worldwide. Diagnosis of the condition is currently limited to utilization of nonspecific signs and symptoms. However, identification of potential pathogenic biomarkers may support earlier diagnosis and ultimately improved prognosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Content<\/jats:title>\n                  <jats:p>The current models of preeclampsia suggest that the disease has components of abnormal placentation, a degree of angiogenic imbalance and endothelial dysfunction. Angiogenic factors such as soluble fms-like tyrosine kinase-1 and soluble endoglin increase while placental growth factor concentrations decrease in the circulation weeks before the onset of the disease. Multiple studies have looked at the capacity of angiogenic factors for the prediction of preeclampsia and adverse pregnancy outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>The goal of this review is to focus on the role of angiogenic factors in the pathogenesis of preeclampsia and use of angiogenic biomarkers for risk stratification, diagnosis, and prognosis of the disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/clinchem\/hvab281","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T20:12:48Z","timestamp":1641413568000},"page":"771-781","source":"Crossref","is-referenced-by-count":25,"title":["Angiogenic Biomarkers for Risk Stratification in Women with Preeclampsia"],"prefix":"10.1093","volume":"68","author":[{"given":"Nikolina","family":"Docheva","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of Chicago Medicine, Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Arenas","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of Chicago Medicine, Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin M","family":"Nieman","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago Medicine, Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Lopes-Perdigao","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of Chicago Medicine, Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4708-8420","authenticated-orcid":false,"given":"Kiang-Teck J","family":"Yeo","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago Medicine, Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarosh","family":"Rana","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of Chicago Medicine, Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,29]]},"reference":[{"key":"2022060107143089100_hvab281-B1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/j.semperi.2009.02.010","article-title":"The global impact of pre-eclampsia and eclampsia","volume":"33","author":"Duley","year":"2009","journal-title":"Semin Perinatol"},{"key":"2022060107143089100_hvab281-B2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.earlhumdev.2016.09.007","article-title":"Preeclampsia; short and long-term consequences for mother and neonate","volume":"102","author":"Bokslag","year":"2016","journal-title":"Early Hum Dev"},{"key":"2022060107143089100_hvab281-B3","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/CIRCRESAHA.118.313276","article-title":"Preeclampsia pathophysiology, challenges, and perspectives","volume":"124","author":"Rana","year":"2019","journal-title":"Circ Res"},{"key":"2022060107143089100_hvab281-B4","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","article-title":"ACOG Practice Bulletin, Number 222","volume":"135","author":"Gestational hypertension and preeclampsia","year":"2020","journal-title":"Obstet Gynecol"},{"key":"2022060107143089100_hvab281-B5","first-page":"261","article-title":"Prediction of adverse outcomes by common definitions of hypertension in pregnancy","volume":"97","author":"Zhang","year":"2001","journal-title":"Obstet Gynecol"},{"key":"2022060107143089100_hvab281-B6","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"N Engl J Med"},{"key":"2022060107143089100_hvab281-B7","first-page":"900","article-title":"Diagnosis and treatment of hypertensive pregnancy disorders","volume":"75","author":"Stepan","year":"2015","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"2022060107143089100_hvab281-B8","author":"NICE","year":"2016."},{"key":"2022060107143089100_hvab281-B9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijgo.12802","article-title":"The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention","volume":"145","author":"Poon","year":"2019","journal-title":"Int J Gynecol Obstet"},{"key":"2022060107143089100_hvab281-B10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41581-019-0119-6","article-title":"Pre-eclampsiapathogenesis, novel diagnostics and therapies","volume":"15","author":"Phipps","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"2022060107143089100_hvab281-B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preghy.2016.02.001","article-title":"Imitators of preeclampsia: a review","volume":"6","author":"Morton","year":"2016","journal-title":"Pregnancy Hypertens"},{"key":"2022060107143089100_hvab281-B12","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.1471-0528.1998.tb09971.x","article-title":"Does gestational hypertension become pre-eclampsia?","volume":"105","author":"Saudan","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"key":"2022060107143089100_hvab281-B13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1479-828X.2005.00382.x","article-title":"Routine investigations might be useful in pre-eclampsia, but not in gestational hypertension","volume":"45","author":"Bailey","year":"2005","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"2022060107143089100_hvab281-B14","doi-asserted-by":"crossref","first-page":"i1753","DOI":"10.1136\/bmj.i1753","article-title":"Clinical risk factors for pre-eclampsia determined in early pregnancy systematic review and meta-analysis of large cohort studies","volume":"353","author":"Bartsch","year":"2016","journal-title":"BMJ"},{"key":"2022060107143089100_hvab281-B15","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/HYPERTENSIONAHA.113.01892","article-title":"Spiral artery remodeling and trophoblast invasion in preeclampsia and fetal growth restriction relationship to clinical outcome","volume":"62","author":"Lyall","year":"2013","journal-title":"Hypertension"},{"key":"2022060107143089100_hvab281-B16","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/sj.ki.5002175","article-title":"Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1","volume":"71","author":"Makris","year":"2007","journal-title":"Kidney Int"},{"key":"2022060107143089100_hvab281-B17","first-page":"378","article-title":"Uterine artery Doppler flow velocity waveforms in the second trimester for the prediction of preeclampsia and fetal growth retardation","volume":"83","author":"North","year":"1994","journal-title":"Obstet Gynecol"},{"key":"2022060107143089100_hvab281-B18","article-title":"Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders","author":"Rana","year":"2020","journal-title":"Am J Obstet Gyneco"},{"key":"2022060107143089100_hvab281-B19","first-page":"69","article-title":"Placental-specific sFLT-1: role in pre-eclamptic pathophysiology and its translational possibilities for clinical prediction and diagnosis","volume":"23","author":"Palmer","year":"2017","journal-title":"Mol Hum Reprod"},{"key":"2022060107143089100_hvab281-B20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/376062a0","article-title":"Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice","volume":"376","author":"Shalaby","year":"1995","journal-title":"Nature"},{"key":"2022060107143089100_hvab281-B21","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1080\/14767058.2018.1443066","article-title":"Placental growth factor, vascular endothelial growth factor, and hypoxia-inducible factor-1\u03b1 in the placentas of women with pre-eclampsia","volume":"32","author":"Ali","year":"2019","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2022060107143089100_hvab281-B22","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"key":"2022060107143089100_hvab281-B23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1172\/JCI17189","article-title":"Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia","volume":"111","author":"Maynard","year":"2003","journal-title":"J Clin Invest"},{"key":"2022060107143089100_hvab281-B24","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia","volume":"350","author":"Levine","year":"2004","journal-title":"N Engl J Med"},{"key":"2022060107143089100_hvab281-B25","doi-asserted-by":"crossref","first-page":"e0116508","DOI":"10.1371\/journal.pone.0116508","article-title":"Large scale aggregate microarray analysis reveals three distinct molecular subclasses of human preeclampsia","volume":"10","author":"Leavey","year":"2015","journal-title":"PLoS One"},{"key":"2022060107143089100_hvab281-B26","doi-asserted-by":"crossref","first-page":"12139","DOI":"10.1038\/s41598-017-11639-6","article-title":"FLT1 and transcriptome-wide polyadenylation site (PAS) analysis in preeclampsia","volume":"7","author":"Ashar-Patel","year":"2017","journal-title":"Sci Rep"},{"key":"2022060107143089100_hvab281-B27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14767050701830480","article-title":"A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate","volume":"21","author":"Romero","year":"2008","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2022060107143089100_hvab281-B28","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1097\/01.AOG.0000264552.85436.a1","article-title":"Placental growth factor and soluble fms-like tyrosine kinase-1 in early-onset and late-onset preeclampsia","volume":"109","author":"Wikstr\u00f6m","year":"2007","journal-title":"Obstet Gynecol"},{"key":"2022060107143089100_hvab281-B29","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1161\/01.RES.0000147365.86159.f5","article-title":"Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia","volume":"95","author":"Ahmad","year":"2004","journal-title":"Circ Res"},{"key":"2022060107143089100_hvab281-B30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3389\/fendo.2019.00165","article-title":"Human sFLT1 leads to severe changes in placental differentiation and vascularization in a transgenic hsFLT1\/rtTA FGR mouse model","volume":"10","author":"Vogtmann","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2022060107143089100_hvab281-B31","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1161\/HYPERTENSIONAHA.109.141937","article-title":"Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension","volume":"55","author":"Gilbert","year":"2010","journal-title":"Hypertension"},{"key":"2022060107143089100_hvab281-B32","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1172\/JCI83918","article-title":"Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia","volume":"126","author":"Burke","year":"2016","journal-title":"J Clin Invest"},{"key":"2022060107143089100_hvab281-B33","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/ng.3895","article-title":"Variants in the fetal genome near FLT1 are associated with risk of preeclampsia","volume":"49","author":"McGinnis","year":"2017","journal-title":"Nat Genet"},{"key":"2022060107143089100_hvab281-B34","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1681\/ASN.2015020157","article-title":"Removal of soluble fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia","volume":"27","author":"Thadhani","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2022060107143089100_hvab281-B35","doi-asserted-by":"crossref","first-page":"8714","DOI":"10.3390\/ijms21228714","article-title":"PlGF immunological impact during pregnancy","volume":"21","author":"Albonici","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2022060107143089100_hvab281-B36","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1161\/CIRCULATIONAHA.109.895458","article-title":"Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension","volume":"122","author":"Noori","year":"2010","journal-title":"Circulation"},{"key":"2022060107143089100_hvab281-B37","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1210\/jc.2003-030528","article-title":"Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patientspathophysiological consequences","volume":"88","author":"Tsatsaris","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2022060107143089100_hvab281-B38","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/HYPERTENSIONAHA.120.15338","article-title":"Total versus free placental growth factor levels in the pathogenesis of preeclampsia","volume":"76","author":"Lecarpentier","year":"2020","journal-title":"Hypertension"},{"key":"2022060107143089100_hvab281-B39","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/rep.1.01076","article-title":"TGF-beta superfamily expression and actions in the endometrium and placenta","volume":"132","author":"Jones","year":"2006","journal-title":"Reproduction"},{"key":"2022060107143089100_hvab281-B40","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1056\/NEJMoa055352","article-title":"Soluble endoglin and other circulating antiangiogenic factors in preeclampsia","volume":"355","author":"Levine","year":"2006","journal-title":"N Engl J Med"},{"key":"2022060107143089100_hvab281-B41","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ejogrb.2021.01.039","article-title":"Soluble endoglin concentration in maternal blood as a diagnostic biomarker of preeclampsia: a systematic review and meta-analysis","volume":"258","author":"Margioula-Siarkou","year":"2021","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2022060107143089100_hvab281-B42","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/aje\/kwq373","article-title":"Angiogenic factors in maternal circulation and the risk of severe fetal growth restriction","volume":"173","author":"\u00c5svold","year":"2011","journal-title":"Am J Epidemiol"},{"key":"2022060107143089100_hvab281-B43","doi-asserted-by":"crossref","first-page":"152.e1","DOI":"10.1016\/j.ajog.2010.08.049","article-title":"Circulating angiogenic and antiangiogenic factors in women with eclampsia","volume":"204","author":"Vaisbuch","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"2022060107143089100_hvab281-B44","article-title":"The prediction of preeclampsia: the way forward.","author":"Myatt","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"2022060107143089100_hvab281-B45","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/uog.17455","article-title":"Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11\u201313 weeks' gestation: comparison with NICE guidelines and ACOG recommendations","volume":"49","author":"O'Gorman","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2022060107143089100_hvab281-B46","article-title":"First trimester preeclampsia screening and prediction","author":"Chaemsaithong","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"2022060107143089100_hvab281-B47","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/uog.19112","article-title":"Screening for pre-eclampsia by maternal factors and biomarkers at 11\u201313 weeks' gestation","volume":"52","author":"Tan","year":"2018","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2022060107143089100_hvab281-B48","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1414838","article-title":"Predictive value of the sFlt-1: PlGF ratio in women with suspected preeclampsia","volume":"374","author":"Zeisler","year":"2016","journal-title":"N Engl J Med"},{"key":"2022060107143089100_hvab281-B49","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.preghy.2018.05.008","article-title":"Angiogenic biomarkers in triage and risk for preeclampsia with severe features","volume":"13","author":"Rana","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"2022060107143089100_hvab281-B50","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/HYPERTENSIONAHA.119.12760","article-title":"Short-term prediction of adverse outcomes using the sFlt-1 (soluble fms-like tyrosine kinase 1)\/PlGF (placental growth factor) ratio in Asian women with suspected preeclampsia","volume":"74","author":"Bian","year":"2019","journal-title":"Hypertension"},{"key":"2022060107143089100_hvab281-B51","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/uog.19178","article-title":"Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting","volume":"53","author":"Zeisler","year":"2019","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2022060107143089100_hvab281-B52","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3109\/14767050902994754","article-title":"A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia","volume":"22","author":"Kusanovic","year":"2009","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2022060107143089100_hvab281-B53","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.116.08620","article-title":"Prediction of Preeclampsia using the soluble fms-like tyrosine kinase 1 to placental growth factor ratio: a prospective cohort study of unselected nulliparous women","volume":"69","author":"Sovio","year":"2017","journal-title":"Hypertension"},{"key":"2022060107143089100_hvab281-B54","doi-asserted-by":"crossref","first-page":"259.e1","DOI":"10.1016\/j.ajog.2019.09.003","article-title":"Placental growth factor predicts time to delivery in women with signs or symptoms of early preterm preeclampsiaa prospective multicenter study","volume":"222","author":"Barton","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"2022060107143089100_hvab281-B55","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/CIRCULATIONAHA.111.054361","article-title":"Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia","volume":"125","author":"Rana","year":"2012","journal-title":"Circulation"},{"key":"2022060107143089100_hvab281-B56","doi-asserted-by":"crossref","first-page":"e0126815","DOI":"10.1371\/journal.pone.0126815","article-title":"Circulating Angiogenic factors and the risk of adverse outcomes among Haitian women with preeclampsia","volume":"10","author":"March","year":"2015","journal-title":"PLoS One"},{"key":"2022060107143089100_hvab281-B57","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/HYPERTENSIONAHA.112.195065","article-title":"Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia","volume":"60","author":"Rana","year":"2012","journal-title":"Hypertension"},{"key":"2022060107143089100_hvab281-B58","doi-asserted-by":"crossref","first-page":"58.e1-8","DOI":"10.1016\/j.ajog.2011.07.037","article-title":"The sFlt-1\/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients","volume":"206","author":"Verlohren","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"2022060107143089100_hvab281-B59","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/ki.2012.348","article-title":"Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers","volume":"83","author":"Rolfo","year":"2013","journal-title":"Kidney Int"},{"key":"2022060107143089100_hvab281-B60","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3109\/14767050903184207","article-title":"The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome","volume":"23","author":"Young","year":"2010","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2022060107143089100_hvab281-B61","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/14767050701413022","article-title":"Unexplained fetal death: another anti-angiogenic state","volume":"20","author":"Espinoza","year":"2007","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2022060107143089100_hvab281-B62","doi-asserted-by":"crossref","first-page":"310.e1","DOI":"10.1016\/j.ajog.2013.01.017","article-title":"Evidence of an imbalance of angiogenic\/antiangiogenic factors in massive perivillous fibrin deposition (maternal floor infarction): a placental lesion associated with recurrent miscarriage and fetal death","volume":"208","author":"Whitten","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"2022060107143089100_hvab281-B63","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature11040","article-title":"Cardiac angiogenic imbalance leads to peripartum cardiomyopathy","volume":"485","author":"Patten","year":"2012","journal-title":"Nature"},{"key":"2022060107143089100_hvab281-B64","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/S0140-6736(18)33212-4","article-title":"Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial","volume":"393","author":"Duhig","year":"2019","journal-title":"Lancet"},{"key":"2022060107143089100_hvab281-B65","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.preghy.2020.10.005","article-title":"Placental growth factor measurements in the assessment of women with suspected preeclampsia: a stratified analysis of the PARROT trial","volume":"23","author":"Duhig","year":"2021","journal-title":"Pregnancy Hypertens"},{"key":"2022060107143089100_hvab281-B66","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/HYPERTENSIONAHA.119.12739","article-title":"Randomized interventional study on prediction of preeclampsia\/eclampsia in women with suspected preeclampsia: INSPIRE","volume":"74","author":"Cerdeira","year":"2019","journal-title":"Hypertension"},{"key":"2022060107143089100_hvab281-B67","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1161\/HYPERTENSIONAHA.120.15146","article-title":"Prediction of preeclampsia-related adverse outcomes with the sFlt-1 (soluble fms-like tyrosine kinase 1)\/PlGF (placental growth factor)-ratio in the clinical routine: a real-world study","volume":"77","author":"Dr\u00f6ge","year":"2021","journal-title":"Hypertension"},{"key":"2022060107143089100_hvab281-B68","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3109\/10641955.2016.1148162","article-title":"KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes","volume":"35","author":"Salahuddin","year":"2016","journal-title":"Hypertens Pregnancy"},{"key":"2022060107143089100_hvab281-B69","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.preghy.2017.12.009","article-title":"Analytical validation of soluble fms-like tyrosine and placental growth factor assays on B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S KRYPTOR Compact Plus automated immunoassay platform","volume":"11","author":"Chan","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"2022060107143089100_hvab281-B70","doi-asserted-by":"crossref","first-page":"100394","DOI":"10.1016\/j.ajogmf.2021.100394","article-title":"Use of the angiogenic biomarker profile to risk stratify patients with intrauterine growth restriction","volume":"3","author":"Arenas","year":"2021","journal-title":"Am J Obstet Gynecol MFM"},{"key":"2022060107143089100_hvab281-B71","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.preghy.2018.06.017","article-title":"Clinical implementation of the sFlt-1\/PlGF ratio to identify preeclampsia and fetal growth restriction: a prospective cohort study","volume":"13","author":"Herraiz","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"2022060107143089100_hvab281-B72","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.preghy.2020.03.002","article-title":"Correlation of Kryptor and Elecsys\u00ae immunoassay sFlt-1\/PlGF ratio on early diagnosis of preeclampsia and fetal growth restriction: a case-control study","volume":"20","author":"Sim\u00f3n","year":"2020","journal-title":"Pregnancy Hypertens"},{"issue":"10","key":"2022060107143089100_hvab281-B73","first-page":"CD004659","article-title":"Antiplatelet agents for preventing pre-eclampsia and its complications","volume":"2019","author":"Duley","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2022060107143089100_hvab281-B74","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.3390\/jcm8091429","article-title":"Effect of low-dose aspirin on soluble fms-like tyrosine kinase 1\/placental growth factor (sFlt-1\/PlGF Ratio) in pregnancies at high risk for the development of preeclampsia","volume":"8","author":"Mayer-Pickel","year":"2019","journal-title":"J Clin Med"},{"key":"2022060107143089100_hvab281-B75","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11906-020-1026-8","article-title":"Novel interventions for the prevention of preeclampsia","volume":"22","author":"Ma'ayeh","year":"2020","journal-title":"Curr Hypertens Rep"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/68\/6\/771\/43914710\/hvab281.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/68\/6\/771\/43914710\/hvab281.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T07:15:42Z","timestamp":1654067742000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/68\/6\/771\/6517152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,29]]},"references-count":75,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,1,29]]},"published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/clinchem\/hvab281","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,1,29]]}}}